Iptd-694 Best 〈2027〉

| Model | Dosing Regimen | Endpoints | Outcome | |-------|----------------|-----------|---------| | | PO 30 mg/kg daily, 7 days | IL‑1β/IL‑18 in CSF, microglial Iba‑1 staining | >80 % reduction in cytokines, 70 % ↓ microglial activation | | APP/PS1 transgenic AD model | PO 25 mg/kg BID, 12 weeks | Amyloid plaque load (Thioflavin‑S), Morris water maze | 35 % ↓ plaque area, significant improvement in spatial memory (p < 0.01) | | MPTP Parkinsonian mouse | PO 20 mg/kg QD, 14 days | TH‑positive neurons in SNpc, motor rotarod performance | 40 % preservation of TH‑cells, 30 % ↑ latency on rotarod | | TBI (controlled cortical impact, rat) | PO 15 mg/kg within 2 h, then QD for 7 days | Edema (MRI), IL‑1β, NF‑κB activation | ↓ edema volume (45 %), cytokine suppression (≈70 %) |